Erratum to: Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study)

被引：0
|
作者：
Pere Gascón
Matti Aapro
Heinz Ludwig
Carsten Bokemeyer
Mario Boccadoro
Matthew Turner
Kris Denhaerynck
Karen MacDonald
Ivo Abraham
机构：
[1] University of Barcelona,Division of Medical Oncology, Department of Hematology
[2] Clinique de Genolier,Oncology, Hospital Clínic de Barcelona
[3] Wilhelminenspital,Institut Multidisciplinaire d’Oncologie
[4] Universitaetsklinikum Hamburg Eppendorf,Medizinische Abteilung I–Onkologie und Haematologie
[5] Universitaria S. Giovanni Battista di Torino,Dipartimento di Oncologia e Ematologia, Azienda Ospedaliero
[6] Sandoz Biopharmaceuticals,Center for Health Outcomes and PharmacoEconomic Research
[7] University of Arizona,undefined
来源：
Supportive Care in Cancer | 2016年 / 24卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：927 / 927
相关论文
共 50 条
  • [31] THE EFFECTIVENESS AND SAFETY OF SWITCHING FROM ORGINAL FILGRASTIM TO BIOSIMILAR FILGRASTIM IN PRIMARY PROPHYLAXIS OF CHEMOTHERAPY INDUCED FEBRILE NEUTROPENIA: A RETROSPECTIVE COHORT STUDY
    Al Rabayah, A. A.
    Hammoudeh, S.
    Mashni, O.
    Hanoun, E.
    Al Qasem, W.
    AL Momani, D.
    VALUE IN HEALTH, 2018, 21 : S20 - S20
  • [32] Biosimilar filgrastim vs filgrastim: a multicenter nationwide observational bioequivalence study in patients with chemotherapy-induced neutropenia
    Sevinc, Alper
    Ozkan, Metin
    Ozet, Ahmet
    Dane, Faysal
    Oksuzoglu, Berna
    Isikdogan, Abdurrahman
    Ozdemir, Feyyaz
    Uncu, Dogan
    Gumus, Mahmut
    Evrensel, Turkkan
    Yaren, Arzu
    Kara, Oguz
    Tekin, Salim Basol
    ONCOTARGETS AND THERAPY, 2018, 11 : 419 - 426
  • [33] Cost-efficiency analyses for the US of biosimilar filgrastim-sndz, reference filgrastim, pegfilgrastim, and pegfilgrastim with on-body injector in the prophylaxis of chemotherapy-induced (febrile) neutropenia
    McBride, Ali
    Campbell, Kim
    Bikkina, Mohan
    MacDonald, Karen
    Abraham, Ivo
    Balu, Sanjeev
    JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (10) : 1083 - 1093
  • [34] Expanded Access to Obinutuzumab from Cost-Savings Generated By Biosimilar Filgrastim-Sndz in the Prophylaxis of Chemotherapy-Induced (Febrile) Neutropenia: US Simulation Study
    McBride, Ali
    Campbell, Kim
    Bikkina, Mohan
    MacDonald, Karen
    Abraham, Ivo
    Balu, Sanjeev
    BLOOD, 2017, 130
  • [35] Budget Saving Potential of Pegfilgrastim Biosimilar for the Treatment of Chemotherapy-Induced Febrile Neutropenia, in Italy
    Berto, Patrizia
    Bellone, Marco
    Sabinot, Alice
    Pinto, Carmine
    Martino, Massimo
    Generali, Daniele
    Carriero, Pier Luigi
    Sanna, Maria Domenica
    FARMECONOMIA-HEALTH ECONOMICS AND THERAPEUTIC PATHWAYS, 2022, 23 (01) : 1 - 12
  • [36] Effectiveness and Safety of Filgrastim (Neupogen™) versus Filgrastim-aafi (Nivestim™) in Primary Prophylaxis of Chemotherapy-Induced Febrile Neutropenia: An Observational Cohort Study
    Abeer A. Al-Rabayah
    Ola Al Mashni
    Esraa Hanoun
    Weam Al Qasem
    Deema Al Momani
    Rawan Fawzi Al Froukh
    Razan Sawalha
    Suzan S. Hammoudeh
    Drugs - Real World Outcomes, 2022, 9 : 589 - 595
  • [37] Effectiveness and Safety of Filgrastim (Neupogen™) versus Filgrastim-aafi (Nivestim™) in Primary Prophylaxis of Chemotherapy-Induced Febrile Neutropenia: An Observational Cohort Study
    Al-Rabayah, Abeer A.
    Al Mashni, Ola
    Hanoun, Esraa
    Al Qasem, Weam
    Al Momani, Deema
    Al Froukh, Rawan Fawzi
    Sawalha, Razan
    Hammoudeh, Suzan S.
    DRUGS-REAL WORLD OUTCOMES, 2022, 9 (04) : 589 - 595
  • [38] Proof-of-concept of a risk calculator of chemotherapy induced (febrile) neutropenia (CIN/FN) based on real-world evidence (Monitor-GCSF study)
    Bokemeyer, C.
    Aapro, M.
    Ludwig, H.
    Gascon, P.
    Boccadoro, M.
    Denhaerynck, K.
    Krendyukov, A.
    Macdonald, K.
    Abraham, I.
    ANNALS OF ONCOLOGY, 2017, 28
  • [39] A Comparison of Brand and Biosimilar Granulocyte-Colony Stimulating Factors for Prophylaxis of Chemotherapy-Induced Febrile Neutropenia
    Douglas, Andrea G.
    Schwab, Phil
    Lane, Daniel
    Kennedy, Kenneth
    Slabaugh, S. Lane
    Bowe, Andy
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2017, 23 (12): : 1221 - 1226
  • [40] Comparison of sargramostim and filgrastim in the treatment a of chemotherapy-induced neutropenia
    Stull, DM
    Bilmes, R
    Kim, H
    Fichtl, R
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2005, 62 (01) : 83 - 87
12345